SCHEMBL7229664

SCHEMBL7229664

Cc1ccnc(-c2ccc(/C=N/O)cc2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CCR1 P32246 1/20 0.50
▸ CCR5 P51681 1/20 0.50
▸ CCR8 P51685 1/20 0.50
▸ CYP2A6 P11509 1/20 0.45
▸ KDM1A O60341 1/20 0.43
▸ HDAC1 Q13547 1/20 0.43
▸ HDAC6 Q9UBN7 1/20 0.43
▸ RIPK1 Q13546 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ KDM4E B2RXH2 2/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ NPC1 O15118 2/20 0.41
▸ RAB9A P51151 2/20 0.41
▸ CASP3 P42574 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ SENP8 Q96LD8 1/20 0.41
▸ SENP7 Q9BQF6 1/20 0.41
▸ SENP6 Q9GZR1 1/20 0.41
▸ ABL1 P00519 4/20 0.40
▸ BCR P11274 4/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7229668 1.00 CCR1 (0.50) CCR1CCR5CCR8CYP2A6KDM1A
SCHEMBL31695263 0.80 CCR1 (0.76) CCR1CCR5CCR8CYP2A6KDM1A
SCHEMBL27344644 0.80 CCR1 (0.76) CCR1CCR5CCR8CYP2A6KDM1A
SCHEMBL7236054 0.78 CCR1 (0.55) CCR1CCR5CCR8CYP2A6KDM1A
SCHEMBL29463685 0.77 CCR1 (0.70) CCR1CCR5CCR8CYP2A6KDM1A
SCHEMBL6807225 0.77 CCR1 (0.70) CCR1CCR5CCR8CYP2A6KDM1A
SCHEMBL17406767 0.75 CCR1 (0.61) CCR1CCR5CCR8CYP2A6KMT2A
SCHEMBL506255 0.75 CA12 (0.52) CCR1CCR5CCR8CYP2A6HDAC1
SCHEMBL506256 0.75 CA12 (0.52) CCR1CCR5CCR8CYP2A6HDAC1
SCHEMBL20412761 0.73 CCR1 (0.53) CCR1CCR5CCR8CYP2A6KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6521643-B1 Prevention and/or treatment of nitric oxide synthasey medi-ated diseases such as adult respiratory distress syndrome, myocarditis, synovitis, septic shock, diabetes, ulcerative colitis, cerebral infarction, osteoarthritis FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-02-18 — — US disclosed
EP-1157022-A1 PYRIDINE COMPOUNDS AND THEIR PHARMACEUTICAL USE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-11-28 — — EP disclosed
WO-2000049015-A1 PYRIDINE COMPOUNDS AND THEIR PHARMACEUTICAL USE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-08-24 — — WO disclosed
Send feedback